002788.SHE Luyan Pharma Co Ltd
- Market cap
- CNY 3.77B
- P/E
- 13.5x
- P/B
- 1.08x
- ROE
- 8.4%
- Dividend yield
- 8.33%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002788.SHE undervalued?
Graham number002788.SHE trades 19.4% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Luyan Pharma Co Ltd fundamental analysis
No fundamental analysis for Luyan Pharma Co Ltd yet.
Luyan Pharma Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Luyan Pharma Co Ltd
Luyan Pharma Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products, and prepared slices of traditional Chinese medicine in China. The company distributes medicines, Chinese herbal medicines, medical devices, and others; and provides medical care, elderly care, and wellness services. It also operates pharmaceutical retail chains. The company was formerly known as Luyan (Fujian) Pharma Co. Ltd. and chang…
Full company profileLuyan Pharma Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Luyan Pharma Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.98B | 8.34B | 11.5B | 15.0B | 15.5B | 17.5B | 19.5B | 19.8B | 20.5B | 21.2B | 21.6B |
| Gross Profit | 526M | 644M | 892M | 1.16B | 1.23B | 1.37B | 1.51B | 1.51B | 1.52B | 1.50B | 1.46B |
| Operating Income | 154M | 199M | 261M | 346M | 374M | 406M | 466M | 469M | 458M | 597M | 565M |
| EBITDA | 247M | 305M | 420M | 536M | 594M | 666M | 745M | 756M | 734M | 694M | 531M |
| Net Income | 116M | 131M | 180M | 256M | 267M | 306M | 345M | 364M | 346M | 281M | 283M |
| EPS | 0.37 | 0.40 | 0.55 | 0.78 | 0.74 | 0.79 | 0.89 | 0.94 | 0.89 | 0.72 | 0.73 |
| Balance Sheet | |||||||||||
| Total Assets | 3.51B | 5.13B | 6.07B | 7.54B | 8.43B | 9.99B | 11.8B | 11.8B | 12.6B | 13.4B | 13.0B |
| Total Liabilities | 2.13B | 3.57B | 4.42B | 5.65B | 6.03B | 7.43B | 8.99B | 8.82B | 9.45B | 10.1B | 9.64B |
| Shareholders' Equity | 1.37B | 1.47B | 1.57B | 1.79B | 2.34B | 2.49B | 2.72B | 2.95B | 3.16B | 3.31B | 3.37B |
| Cash & Short-term Investments | 425M | 542M | 517M | 429M | 595M | 415M | 594M | 606M | 577M | 617M | 451M |
| Total Debt | 917M | 1.79B | 2.27B | 3.25B | 3.48B | 4.47B | 5.06B | 4.64B | 4.61B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -128M | -447M | 127M | -629M | 77.2M | -372M | 232M | 1.31B | 577M | 688M | - |
| Capital Expenditure | 110M | 84.2M | 134M | 199M | 171M | 243M | 328M | 529M | 361M | 234M | 182M |
| Free Cash Flow | -238M | -531M | -7.11M | -828M | -93.4M | -616M | -95.4M | 780M | 216M | 455M | -4.34M |
| Ratios | |||||||||||
| ROE | 8.4% | 8.9% | 11.5% | 14.3% | 11.4% | 12.3% | 12.7% | 12.3% | 10.9% | 8.5% | 8.4% |
| ROA | 3.3% | 2.5% | 3.0% | 3.4% | 3.2% | 3.1% | 2.9% | 3.1% | 2.7% | 2.1% | 2.2% |
| Net Profit Margin | 1.7% | 1.6% | 1.6% | 1.7% | 1.7% | 1.7% | 1.8% | 1.8% | 1.7% | 1.3% | 1.3% |
| Debt to Equity | 0.67x | 1.22x | 1.45x | 1.82x | 1.49x | 1.79x | 1.86x | 1.58x | 1.46x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Luyan Pharma Co Ltd dividends
- Dividend yield
- 8.33%
- Forward dividend
- 0.35 CNY
- Payout ratio
- 111.8%
- Ex-dividend date
- Jul 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 314M | 0.81 | 111.8% |
| 2024 | CNY 324M | 0.83 | 93.7% |
| 2023 | CNY 340M | 0.88 | 93.6% |
| 2022 | CNY 117M | 0.30 | 33.8% |
| 2021 | CNY 98.9M | 0.26 | 32.3% |
| 2020 | CNY 49.0M | 0.14 | 18.4% |
| 2019 | CNY 38.5M | 0.12 | 15.0% |
| 2018 | CNY 177M | 0.54 | 98.2% |
| 2017 | CNY 98.3M | 0.30 | 75.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.7:1 on May 29, 2019.
Who owns Luyan Pharma Co Ltd
- Insiders 41.95%
- Institutions 0.63%
- Public & others 57.43%
- Shares outstanding 389M
- Free float 230M
Luyan Pharma Co Ltd company profile
- Company name
- Luyan Pharma Co Ltd
- Ticker
- 002788.SHE
- ISIN
- CNE1000025W1
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 5,722
- Fiscal year end
- December
- Address
- No. 1004, Anling Road, Xiamen, China, 361015
- Phone
- 86 59 2812 8888
- Website
- luyan.com.cn
About Luyan Pharma Co Ltd
Luyan Pharma Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products, and prepared slices of traditional Chinese medicine in China. The company distributes medicines, Chinese herbal medicines, medical devices, and others; and provides medical care, elderly care, and wellness services. It also operates pharmaceutical retail chains. The company was formerly known as Luyan (Fujian) Pharma Co. Ltd. and changed its name to Luyan Pharma Co.,Ltd. in June 2016. Luyan Pharma Co.,Ltd. was founded in 1992 and is headquartered in Xiamen, China.
Luyan Pharma Co Ltd management
8- Mr. Jinxiang WuChairman & GM · born 1962
- Mr. Di WuDeputy GM & Vice Chairman · born 1991
- Ms. Zheng ZengChief Financial Officer · born 1986
- Mr. Lei MingDeputy GM, Chief Compliance Officer & Director · born 1975
- Mr. Quanqing YeSecretary · born 1977
- Mr. Wei Yang LiDeputy General Manager · born 1970
- Ms. Jun Ying ZhangDeputy General Manager · born 1972
- Mr. Jin LiuDeputy General Manager · born 1975